In a prospective, non-interventional, monocentric observational study the pharmacokinetic properties of selected antiinfective drugs during sustained low-efficiency dialysis (SLED) will be analyzed.
Antibiotic concentrations are measured whilst patients receive SLED for renal replacement therapy. The plasma specimens will be quantified using high Performance liquid chromatography (HPLC). Primary endpoint: \- Plasma levels of antiinfectives during SLED Secondary endpoints: * mortality * length of stay at the intensive care unit (ICU) and hospital * clinical cure of infections Inclusion criteria: * age: \> 18 years * patients under SLED * antiinfective treatment exclusion criteria: \- missing informed consent
Study Type
OBSERVATIONAL
Enrollment
35
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC)
Plasma concentrations of meropenem or ceftazidim by the end of SLED therapy. Meropenem and ceftazidim are often used for empirical treatment also targeting for Pseudomonas aeruginosa (PSA) infections. Therefore, minimal targeted concentrations were set to the MIC of 2 mg/l for meropenem and to the MIC of 4 mg/L for ceftazidime treatment according to the breakpoints of PSA strains.
Time frame: days receiving SLED, up to 5 days
Mortality
ICU mortality
Time frame: minimum duration of hospital stay, maximum 1 year
Length of Stay (LOS)
Length of stay at the ICU and in hospital
Time frame: minimum duration of hospital stay, maximum 1 year
Number of Patients With Clinical Cure of Infections
Clinical response to antibiotic treatment assessed by laboratory parameters such as leucocyte count, c-reactive protein or procalcitonin levels as well as vasopressor support
Time frame: minimum duration of hospital stay, maximum 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.